Martin Michels

Biochemistry, Genetics and Molecular Biology · Life Sciences

17h-index1.4kcitations50works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PI3K/AKT/mTOR signaling in cancer(13), Cancer Mechanisms and Therapy(11), Porphyrin and Phthalocyanine Chemistry(10), Chronic Lymphocytic Leukemia Research(7), Synthesis and Biological Evaluation(5)

Publications50 total

Supplementary Materials and Methods; Supplementary Tables 1-6; and Supplementary Figure Legends from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
2023Open Access
Suppl. Figure 3 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
2023Open Access
Suppl. Figure 2 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
2023Open Access
Suppl. Figure 3 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
2023Open Access
Suppl. Figure 4 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
2023Open Access
Suppl. Figure 1 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
2023Open Access
Data from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
2023Open Access
Suppl. Figure 2 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
2023Open Access
Data from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
2023Open Access
Suppl. Figure 4 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
2023Open Access
Suppl. Figure 1 from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
2023Open Access
Supplementary Materials and Methods; Supplementary Tables 1-6; and Supplementary Figure Legends from Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
2023Open Access
Abstract 2: Discovery of BAY 2402234 by phenotypic screening: A human Dihydroorotate Dehydrogenase (DHODH) inhibitor in clinical trials for the treatment of myeloid malignancies
Cancer Chemistry·2019· 2 cited
Abstract 2: Discovery of BAY 2402234 by phenotypic screening: A human Dihydroorotate Dehydrogenase (DHODH) inhibitor in clinical trials for the treatment of myeloid malignancies
Cancer Research·2019· 7 cited
Abstract DDT02-04: BAY 2402234: A novel, selective dihydroorotate dehydrogenase (DHODH) inhibitor for the treatment of myeloid malignancies
Cancer Research·2018· 3 cited
BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity
Cancer Letters·2017· 56 citedOpen Access
BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling‐dependent tumor growth in mouse models
International Journal of Cancer·2016· 59 citedOpen Access
Abstract 341: Preclinical mode of action and anti-tumor efficacy of the selective MKNK1 inhibitor BAY 1143269 in NSCLC models
Cancer Research·2016· 1 cited
Abstract 2645: BAY 1436032: A highly selective, potent and orally available inhibitor of mutant forms of IDH1
Cancer Research·2016· 1 cited
Abstract 379: Allosteric AKT1/2-inhibitor BAY 1125976 as potent inhibitor in luminal breast cancer resistant to antihormone therapy
Cancer Research·2016· 3 cited
page 1 of 3Next →

Frequent Co-authors

Karl Ziegelbauer(21), Dominik Mumberg(21), Roland Neuhaus(19), Franz von Nussbaum(19), Detlef Stoeckigt(17), Antje M. Wengner(16), Philip Lienau(15), Gerhard Siemeister(14), Marcus Koppitz(14), Volker Schulze(14), Ulrich Klar(14), Benjamin Bader(14), Stefan Prechtl(14), Marian Raschke(14), Oliver von Ahsen(14), Bertolt Kreft(14), Anna-Lena Frisk(13), Dirk Kosemund(12), Michael W. Brands(11), Emanuel Vogel(10)